419 related articles for article (PubMed ID: 36496977)
1. Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy.
Kundu M; Greer YE; Dine JL; Lipkowitz S
Cells; 2022 Nov; 11(23):. PubMed ID: 36496977
[TBL] [Abstract][Full Text] [Related]
2. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
[TBL] [Abstract][Full Text] [Related]
3. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
[TBL] [Abstract][Full Text] [Related]
4. Regulation of programmed death ligand 1 (PD-L1) expression by TNF-related apoptosis-inducing ligand (TRAIL) in triple-negative breast cancer cells.
Pimentel JM; Zhou JY; Wu GS
Mol Carcinog; 2023 Feb; 62(2):135-144. PubMed ID: 36239572
[TBL] [Abstract][Full Text] [Related]
5. YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
Pennati M; Sbarra S; De Cesare M; Lopergolo A; Locatelli SL; Campi E; Daidone MG; Carlo-Stella C; Gianni AM; Zaffaroni N
Int J Cancer; 2015 Jan; 136(2):299-309. PubMed ID: 24866585
[TBL] [Abstract][Full Text] [Related]
6. Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
Strekalova E; Malin D; Rajanala H; Cryns VL
Breast Cancer Res Treat; 2017 Jun; 163(3):435-447. PubMed ID: 28324269
[TBL] [Abstract][Full Text] [Related]
7. Pterostilbene Enhances TRAIL-Induced Apoptosis through the Induction of Death Receptors and Downregulation of Cell Survival Proteins in TRAIL-Resistance Triple Negative Breast Cancer Cells.
Hung CM; Liu LC; Ho CT; Lin YC; Way TD
J Agric Food Chem; 2017 Dec; 65(51):11179-11191. PubMed ID: 29164887
[TBL] [Abstract][Full Text] [Related]
8. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer.
Zhu W; Zhang H; Shi Y; Song M; Zhu B; Wei L
Cancer Biol Ther; 2013 Nov; 14(11):1016-23. PubMed ID: 24025362
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
Kim SY; Hong M; Heo SH; Park S; Kwon TK; Sung YH; Oh Y; Lee S; Yi GS; Kim I
Mol Carcinog; 2018 Nov; 57(11):1492-1506. PubMed ID: 29964331
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumour effects of TRAIL-expressing human placental derived mesenchymal stem cells with curcumin-loaded chitosan nanoparticles in a mice model of triple negative breast cancer.
Kamalabadi-Farahani M; Vasei M; Ahmadbeigi N; Ebrahimi-Barough S; Soleimani M; Roozafzoon R
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S1011-S1021. PubMed ID: 30580635
[TBL] [Abstract][Full Text] [Related]
12. Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression.
Strekalova E; Malin D; Good DM; Cryns VL
Clin Cancer Res; 2015 Jun; 21(12):2780-91. PubMed ID: 25724522
[TBL] [Abstract][Full Text] [Related]
13. CSC-3436 sensitizes triple negative breast cancer cells to TRAIL-induced apoptosis through ROS-mediated p38/CHOP/death receptor 5 signaling pathways.
Huang CC; Cheng YC; Lin YC; Chou CH; Ho CT; Wang HK; Way TD
Environ Toxicol; 2021 Dec; 36(12):2578-2588. PubMed ID: 34599545
[TBL] [Abstract][Full Text] [Related]
14. Targeting PP2A inhibits the growth of triple-negative breast cancer cells.
Uddin MH; Pimentel JM; Chatterjee M; Allen JE; Zhuang Z; Wu GS
Cell Cycle; 2020 Mar; 19(5):592-600. PubMed ID: 32011210
[TBL] [Abstract][Full Text] [Related]
15. Developing TRAIL/TRAIL death receptor-based cancer therapies.
Yuan X; Gajan A; Chu Q; Xiong H; Wu K; Wu GS
Cancer Metastasis Rev; 2018 Dec; 37(4):733-748. PubMed ID: 29541897
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels.
Kisim A; Atmaca H; Cakar B; Karabulut B; Sezgin C; Uzunoglu S; Uslu R; Karaca B
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1155-63. PubMed ID: 22411600
[TBL] [Abstract][Full Text] [Related]
17. Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer.
Malin D; Chen F; Schiller C; Koblinski J; Cryns VL
Clin Cancer Res; 2011 Aug; 17(15):5005-15. PubMed ID: 21653692
[TBL] [Abstract][Full Text] [Related]
18. Glutamine metabolism regulates FLIP expression and sensitivity to TRAIL in triple-negative breast cancer cells.
Mauro-Lizcano M; López-Rivas A
Cell Death Dis; 2018 Feb; 9(2):205. PubMed ID: 29434187
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 sensitizes TNF-α and TRAIL/Apo2L dependent cell death through upregulation of death receptors in human cancer cells.
Sano E; Kazaana A; Tadakuma H; Takei T; Yoshimura S; Hanashima Y; Ozawa Y; Yoshino A; Suzuki Y; Ueda T
Biochim Biophys Acta Mol Cell Res; 2021 Jun; 1868(7):119037. PubMed ID: 33839168
[TBL] [Abstract][Full Text] [Related]
20. Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.
Festuccia C; Gravina GL; D'Alessandro AM; Millimaggi D; Di Rocco C; Dolo V; Ricevuto E; Vicentini C; Bologna M
Int J Oncol; 2008 Aug; 33(2):381-8. PubMed ID: 18636160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
